Susan Desmond-Hellmann
Susan Desmond-Hellmann is an American oncologist and biotechnology expert. From 2014 to 2020, she served as CEO of the Bill & Melinda Gates Foundation. In March 2024, she was elected to the board of OpenAI. Prior to that, she served as chancellor—the first woman to hold that position—and as the Arthur and Toni Rembe Rock Distinguished Professor at the University of California, San Francisco (UCSF). Before that, she was President of Product Development at Genentech, where she was involved in the development of the first gene-therapy cancer drugs, Avastin and Herceptin.
| Date of birth | 1958 |
| Place of birth | Napa, California |
| Wikipedia link | https://de.wikipedia.org/wiki/Susan_Desmond-Hellmann |